An FDA report released over the weekend on the eve of Lemtrada's AdCom hearing has unearthed serious and potentially fatal safety concerns with Sanofi's MS drug. The milestone-dependent CVR stock GCVRZ Sanofi established during an acquisition dispute with Genzyme near-collapsed on the news:
Read the full article, "Report slams Genzyme’s MS drug on eve of hearing" here
Read the full article, "Report slams Genzyme’s MS drug on eve of hearing" here
No comments:
Post a Comment